Entertainment news and discussion on TalkFuse.
An Immortality Machine? We’ll Be the Judge of That.
The article profiles the Ammortal Chamber, a luxury wellness device priced at $159,500 that is marketed as a tool for recovery, stress reduction and longevity rather than a medical treatment. Framed through a first-person visit to an upscale Connecticut med spa, the piece explores how the machine fits into a wider culture of affluent wellness and biohacking, where people are increasingly willing to try expensive, technology-driven methods to manage ageing and optimise health. Its significance lies less in proven immortality than in what it reveals about the growing commercial market for longevity products and the celebrity attention helping to legitimise them.
The chamber, released in 2023, combines several non-invasive features including meditation, molecular hydrogen, vibroacoustics, electromagnetics, red light therapy and near-infrared therapy. Its creator, Brian Le Gette, is careful not to present it as a device that heals or cures, saying instead that it is intended to support the body’s own recovery by helping shift users into a calmer parasympathetic state. The article notes endorsements and reported use by high-profile athletes including Matthew Stafford, Mike Trout and Freddie Freeman, while placing the machine alongside other fashionable treatments mentioned at the spa, such as NAD+ infusions and salmon-DNA-based PDRN injections.
In short
- A $159,500 wellness machine is marketed for recovery and longevity.
- The article examines elite biohacking culture and anti-ageing demand.
- Its maker stresses wellness support, not medical treatment.
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Adults should retain freedom to make their own wellness choices, particularly when devices avoid explicit medical claims and combine non-invasive modalities with individual research support. The Ammortal Chamber's creator is notably cautious, positioning it as a recovery and stress-reduction tool rather than a cure, which respects consumers' autonomy to evaluate its merits themselves. If affluent individuals find value in a comprehensive wellness device, that remains their prerogative within a free market.
The case against
Devices marketed for longevity at $159,500 exploit wealthy consumers' deep anxieties about ageing and mortality by suggesting unproven solutions, even whilst avoiding explicit medical claims that would trigger regulatory oversight. The combination of celebrity endorsements, vague wellness language, and premium pricing creates an aura of legitimacy that substantially outpaces any rigorous scientific evidence for the device's dramatic claims. This pattern separates the wealthy from substantial sums based on marketing allure rather than proof of efficacy, enabled by regulatory gaps between wellness and medical categories.
Explained simply
The Ammortal Chamber is a wellness device costing $159,500 that combines meditation with several techniques including red light therapy, electromagnetic stimulation, hydrogen therapy and sound vibrations. It is marketed as a tool for recovery and stress reduction, with its creator emphasising that it works by helping the body shift into a calmer state.
The chamber was released in 2023 and has reportedly attracted attention from high-profile athletes including baseball players Mike Trout and Freddie Freeman, as well as American football quarterback Matthew Stafford. The device sits within a broader wellness culture where wealthy individuals are increasingly willing to invest in expensive technology-based treatments designed to manage ageing and enhance their health and performance.
The Ammortal Chamber is part of a growing commercial market for longevity products aimed at wealthy consumers. Whilst the device itself is framed around wellness rather than medical claims, the celebrity endorsements and expansion of such offerings in upscale wellness spaces reflect broader shifts in how people with disposable income approach health and ageing.